137 related articles for article (PubMed ID: 29371923)
1. Targeting the
Caporali S; Alvino E; Lacal PM; Ruffini F; Levati L; Bonmassar L; Scoppola A; Marchetti P; Mastroeni S; Antonini Cappellini GC; D'Atri S
Oncotarget; 2017 Dec; 8(69):113472-113493. PubMed ID: 29371923
[TBL] [Abstract][Full Text] [Related]
2. Targeting the PI3K/AKT/mTOR pathway overcomes the stimulating effect of dabrafenib on the invasive behavior of melanoma cells with acquired resistance to the BRAF inhibitor.
Caporali S; Alvino E; Lacal PM; Levati L; Giurato G; Memoli D; Caprini E; Antonini Cappellini GC; D'Atri S
Int J Oncol; 2016 Sep; 49(3):1164-74. PubMed ID: 27572607
[TBL] [Abstract][Full Text] [Related]
3. miR-126-3p down-regulation contributes to dabrafenib acquired resistance in melanoma by up-regulating ADAM9 and VEGF-A.
Caporali S; Amaro A; Levati L; Alvino E; Lacal PM; Mastroeni S; Ruffini F; Bonmassar L; Antonini Cappellini GC; Felli N; Carè A; Pfeffer U; D'Atri S
J Exp Clin Cancer Res; 2019 Jun; 38(1):272. PubMed ID: 31227006
[TBL] [Abstract][Full Text] [Related]
4. Down-regulation of the PTTG1 proto-oncogene contributes to the melanoma suppressive effects of the cyclin-dependent kinase inhibitor PHA-848125.
Caporali S; Alvino E; Levati L; Esposito AI; Ciomei M; Brasca MG; Del Bufalo D; Desideri M; Bonmassar E; Pfeffer U; D'Atri S
Biochem Pharmacol; 2012 Sep; 84(5):598-611. PubMed ID: 22704958
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma.
Fofaria NM; Frederick DT; Sullivan RJ; Flaherty KT; Srivastava SK
Oncotarget; 2015 Dec; 6(38):40535-56. PubMed ID: 26497853
[TBL] [Abstract][Full Text] [Related]
6. Imaging markers of response to combined BRAF and MEK inhibition in BRAF mutated vemurafenib-sensitive and resistant melanomas.
Acciardo S; Mignion L; Joudiou N; Bouzin C; Baurain JF; Gallez B; Jordan BF
Oncotarget; 2018 Mar; 9(24):16832-16846. PubMed ID: 29682188
[TBL] [Abstract][Full Text] [Related]
7. The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4.
Liu L; Mayes PA; Eastman S; Shi H; Yadavilli S; Zhang T; Yang J; Seestaller-Wehr L; Zhang SY; Hopson C; Tsvetkov L; Jing J; Zhang S; Smothers J; Hoos A
Clin Cancer Res; 2015 Apr; 21(7):1639-51. PubMed ID: 25589619
[TBL] [Abstract][Full Text] [Related]
8. FoxM1 transactivates PTTG1 and promotes colorectal cancer cell migration and invasion.
Zheng Y; Guo J; Zhou J; Lu J; Chen Q; Zhang C; Qing C; Koeffler HP; Tong Y
BMC Med Genomics; 2015 Aug; 8():49. PubMed ID: 26264222
[TBL] [Abstract][Full Text] [Related]
9. Alteration of Pituitary Tumor Transforming Gene-1 Regulates Trophoblast Invasion via the Integrin/Rho-Family Signaling Pathway.
Lim SM; Jang HY; Lee JE; Shin JS; Park SH; Yoon BH; Kim GJ
PLoS One; 2016; 11(2):e0149371. PubMed ID: 26900962
[TBL] [Abstract][Full Text] [Related]
10. Dabrafenib plus Trametinib: a Review in Advanced Melanoma with a BRAF (V600) Mutation.
Dhillon S
Target Oncol; 2016 Jun; 11(3):417-28. PubMed ID: 27246822
[TBL] [Abstract][Full Text] [Related]
11. Dabrafenib for the treatment of BRAF V600-positive melanoma: a safety evaluation.
Rutkowski P; Blank C
Expert Opin Drug Saf; 2014 Sep; 13(9):1249-58. PubMed ID: 25014231
[TBL] [Abstract][Full Text] [Related]
12. Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies.
Gibney GT; Zager JS
Expert Opin Drug Metab Toxicol; 2013 Jul; 9(7):893-9. PubMed ID: 23621583
[TBL] [Abstract][Full Text] [Related]
13. Low Doses of Celecoxib Might Promote Phenotype Switching in Cutaneous Melanoma Treated with Dabrafenib-Preliminary Study.
Tudor DV; Florea A; Cenariu M; Olteanu DE; Farcaș M; Hopârtean A; Clichici SV; Filip GA
J Clin Med; 2022 Aug; 11(15):. PubMed ID: 35956175
[TBL] [Abstract][Full Text] [Related]
14. Involvement of pituitary tumor transforming gene 1 in psoriasis, seborrheic keratosis, and skin tumors.
Cai SQ; Dou TT; Li W; Li SQ; Chen JQ; Zhou J; Zheng M; Man XY
Discov Med; 2014 Dec; 18(101):289-99. PubMed ID: 25549700
[TBL] [Abstract][Full Text] [Related]
15. The PTTG1-targeting miRNAs miR-329, miR-300, miR-381, and miR-655 inhibit pituitary tumor cell tumorigenesis and are involved in a p53/PTTG1 regulation feedback loop.
Liang HQ; Wang RJ; Diao CF; Li JW; Su JL; Zhang S
Oncotarget; 2015 Oct; 6(30):29413-27. PubMed ID: 26320179
[TBL] [Abstract][Full Text] [Related]
16. A cost-effectiveness analysis of trametinib plus dabrafenib as first-line therapy for metastatic BRAF V600-mutated melanoma in the Swiss setting.
Matter-Walstra K; Braun R; Kolb C; Ademi Z; Dummer R; Pestalozzi BC; Schwenkglenks M
Br J Dermatol; 2015 Dec; 173(6):1462-70. PubMed ID: 26332527
[TBL] [Abstract][Full Text] [Related]
17. Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma.
Carlos G; Anforth R; Clements A; Menzies AM; Carlino MS; Chou S; Fernandez-Peñas P
JAMA Dermatol; 2015 Oct; 151(10):1103-9. PubMed ID: 26200476
[TBL] [Abstract][Full Text] [Related]
18. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
Menzies AM; Long GV
Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796
[TBL] [Abstract][Full Text] [Related]
19. Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.
Corcoran RB; Atreya CE; Falchook GS; Kwak EL; Ryan DP; Bendell JC; Hamid O; Messersmith WA; Daud A; Kurzrock R; Pierobon M; Sun P; Cunningham E; Little S; Orford K; Motwani M; Bai Y; Patel K; Venook AP; Kopetz S
J Clin Oncol; 2015 Dec; 33(34):4023-31. PubMed ID: 26392102
[TBL] [Abstract][Full Text] [Related]
20. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]